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Abstract
Background: Platelet-endothelial aggregation receptor 1 (PEAR-1) is a transmembrane receptor involved in platelet
activation and megakaryopoiesis whose expression is driven by DNA methylation. PEAR1 variants were associated
with differential platelet response to activation and cardiovascular outcomes. We aimed at investigating the link
between PEAR1 methylation and platelet and leukocyte function markers in a family-based population.
Results: We measured PEAR1 methylation in 605 Moli-family participants with available blood counts, plasma P-
selectin and C-reactive protein, whole blood platelet P-selectin, and platelet-leukocyte mixed conjugate
measurements. We performed principal component analysis (PCA) to identify groups of highly correlated CpG sites.
We used linear mixed regression models (using age, gender, BMI, smoking, alcohol drinking, being a proband for
family recruitment, being a member of myocardial infarction (MI) family as fixed effects, and family as a random
effect) to evaluate associations between PEAR1 methylation and phenotypes. PEAR1 methylation Factor2,
characterized by the previously identified megakaryocyte-specific CpG sites, was inversely associated with platelet-
monocyte conjugates, P-selectin, and WBC counts, while positively associated with the platelet distribution width
(PDW) and with leukocyte CD11b and L-selectin. Moreover, PEAR1 Factor2 methylation was negatively associated
with INFLAscore, a low-grade inflammation score. The latter was partially mediated by the PEAR1 methylation effect
on platelet variables. PEAR1 methylation association with WBC measurements and INFLAscore was confirmed in the
independent cohort FLEMENGHO.
Conclusions: We report a significant link between epigenetic signatures in a platelet functional gene and
inflammation-dependent platelet function variability measured in two independent cohorts.
Introduction
Platelet-endothelial aggregation receptor 1 (PEAR-1) is a
membrane receptor involved in cell-cell interactions,
particularly expressed in platelets, megakaryocytes, and
endothelial cells. PEAR-1 sustains activation of the platelet
integrin αIIbβ3 through its src family kinase (c-Src)-
dependent phosphorylation that stabilizes platelet aggre-
gate formation [1]. The direct activation of PEAR-1 not
only by its pentameric ligand, the FcεR1α chain, but also
by anti-PEAR-1 antibodies, dextran sulfate, synthetic gly-
copolymers, and natural fucoidans triggers potent platelet
aggregation [1–4]. Numerous large studies have identified
PEAR1 genetic variants as determinants of platelet re-
sponse/function variability, both in the general population
and in cohorts with cardiovascular outcomes [5–29],
suggesting that PEAR-1 may be a signaling component,
capable of modulating several functional platelet pathways
in physiological conditions, but also in the context of anti-
platelet therapy and cardiovascular disease. This seems to
be the case in particular for rs12041331 and rs12566888, 2
PEAR1 variants in linkage disequilibrium (LD) located in
intron 1 of the PEAR1 gene locus [30]. In particular,
PEAR1 rs12041331 G/A substitution leads to lower plate-
let PEAR1 expression [6] and reduces endothelial cell mi-
gration in carriers of the A allele [31], while a negative
association of rs12566888 with WBC, neutrophil, and
monocyte numbers in a large-scale Exomechip analysis
has been reported by Eicher and colleagues [25]. The
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latter opened up the possibility for a pleiotropic role of
PEAR1 in influencing not only platelet function variability
but also hematopoiesis at large. Indeed, PEAR1 expres-
sion increases during megakaryocyte (MK) differenti-
ation and PEAR1 knock-down CD34+ cells show higher
proliferation of immature MKs, whereas terminal MK
maturation (proplatelet formation) is not affected in
the absence of PEAR-1 [32]. In addition, expression
profiling on normal human bone marrow sections also
showed transient PEAR1 positivity in myeloid precur-
sors, yet absent in mature granulocytes [32].
We have previously identified a region within the first
untranslated exon of the PEAR1 gene that, towards the
later stages of MK specification, undergoes a significant
increase of DNA methylation level in parallel to PEAR1
expression [30]. We found the same region to be differ-
entially methylated between megakaryocyte and endo-
thelial cells and to be part of a superenhancer that
coordinates expression of multiple genes involved in cell
cycle and cell proliferation through long-range chromo-
some interactions [33]. This type of epigenetic regulation
contributes to the fine-tuning of PEAR1 expression, but
it remains unclear, at the population level, whether
PEAR1 epigenetic variability would contribute to explain
variability of platelet function and would also have an
impact on hematopoiesis and leukocyte function.
In this study, we investigated PEAR1 methylation as
a marker of platelet and leukocyte formation, their
activation and cross-talk, using DNA samples from a
family-based cohort study (the Moli-family study)
[34–36], characterized by a large set of hematological
activation markers. Our major results were replicated
in a second independent population-based cohort (the
FLEMENGHO study) [37–39].
Results
Demographics of the population studied are shown in
Table 1. Blood cell counts, platelet, and leukocyte activa-
tion markers are reported in Table 2.
After removing duplicate units and units with standard
deviation (SD) between replicates higher than 5% as de-
scribed [30, 40, 41], we obtained a total of PEAR1 16
CpG units for further analysis. These PEAR1 CpG sites,
identified for the Moli-family cohort, include the previ-
ously identified megakaryocyte-specific CpG sites [30].
The exact genomic location of each CpG site in PEAR1
is reported in the Additional file 1: Table S1. For each of
these sites, Fig. 1 shows the distribution of the fractional
degree of methylation, uncovering a wide variation in
methylation within and between different sites.
After exclusion of failing samples, a total of 605 Moli-
family participants were included for further analyses.
Mean and SD of PEAR1 CpG sites methylation ranged
from 0.6 ± 1.0% for CpG28–29 up to 90.8 ± 14.1% for
CpG17. Only CpG7–8, 17, and 27 had methylation aver-
ages across the population higher than 10%, while all the
other 13 CpG units appeared less methylated (0 to
10%) (Fig. 1 and Additional file 1: Table S1). Several
of the examined CpGs showed strong inter-correlations
(Additional file 1: Table S2).
Because PEAR1 CpG site methylation showed significant
inter-correlations, we used principal component analysis
(PCA) with the aim of identifying common underlying fac-
tors (patterns) that explain the largest variation in methyla-
tion. For this analysis, 370 individuals were included having
all the PEAR1 CpG units successfully measured. Three-,
four-, and five-factor solutions were discarded on the basis
of the scree plot. Two main methylation factors finally
emerged with PCA. Factor1 is characterized by high posi-
tive loadings of CpGs 4–5, 6, 11–13, 17, 18, 27, and 30, and
Factor2 by that of CpGs 7–8, 15–16, 19–20, 22, 25–26, and
31–32 (Additional file 1: Table S3). Three more CpG units
(CpG1, CpG2, and CpG28–29) did not appear to contrib-
ute to any of the identified methylation factors; therefore,
they were included in further analyses as separate methyla-
tion variables (Table 4 and Additional file 1: Table S4).
PEAR1 methylation is associated with ex vivo platelet-
monocyte mixed aggregates
Linear mixed regression analysis was performed to
assess the relation between PEAR1 methylation patterns
(Factor1, Factor2, CpG1, CpG2 and CpG28–29) and
platelet activation phenotypes, considering whole blood
baseline platelet P-selectin and platelet-monocyte or
Table 1 General characteristics of Moli-family participants
Characteristic Moli-family
Number (%) of participants 605
Women 330 (54.5)
Current smoking 165 (27.4)
Drinking alcohola 122 (21.8)
Hypertension 206 (34.2)
Diabetes 36 (6.0)
Mean (± SD) characteristic
Age, years 42.3 ± 18.8
Body mass index, kg/m2 26.5 ± 5.4
Blood pressure, mm Hg
Systolic 130.2 ± 20.6
Diastolic 77.1 ± 11.6
Total serum cholesterol, mmol/L 5.06 ± 1.10
HDL cholesterol, mmol/L 1.49 ± 0.38
Total-to-HDL cholesterol ratio 3.56 ± 1.03
HDL indicates high-density lipoprotein. Hypertension was a blood pressure of
≥ 140 mmHg systolic or ≥ 90 mmHg diastolic or use of antihypertensive drugs.
Diabetes mellitus was a fasting plasma glucose level of ≥ 7.0 mmol/L or use of
antidiabetic agents
aDefined as drinking at least 15 g of alcohol daily
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platelet-leukocyte mixed conjugates already measured in
the cohort [34]. We found that platelet-monocyte, but not
platelet-polymorphonuclear cell (PMN), mixed conjugates
were consistently negatively associated with PEAR1 Fac-
tor2 methylation (Additional file 1: Table S4) with the as-
sociation explaining 3.5% of platelet-monocyte aggregate
variability (Additional file 1: Table S4). The association be-
tween PEAR1 Factor2 methylation and platelet P-selectin
almost reached significance with a p value of 0.08. PEAR1
Factor1, CpG1, CpG2, and CpG28–29 methylation was
not associated with any of the platelet-specific variables
measured (Additional file 1: Table S4).
In a previous study, focused on the methylation of the
same PEAR1 region, we identified some specific CpG
sites that significantly changed their methylation status
according to PEAR1 expression during differentiation of
megakaryocyte precursors (CpG4–5, 7–8, 11–13, 15–16,
19–20, 22) [30]. Based on that finding, and because
PEAR1 Factor2 mainly depends on these MK-specific
CpG sites (Additional file 1: Table S3), we also per-
formed a specific CpG methylation analysis considering
the 16 PEAR1 CpG units as single measures in the Moli-
family cohort. By using this type of approach, we identi-
fied CpG sites 7–8 and 19–20 as the most significantly
associated PEAR1 sites with platelet P-selectin and
platelet-PMN aggregates (Additional file 1: Table S5).
PEAR1 methylation is associated with white blood cell
measurements
We investigated the possible association of PEAR1 methy-
lation with blood cell counts in the Moli-family cohort.
While no significant association was found with platelet
count, mean platelet volume (MPV), or plateletcrit (Pct),
PEAR1 Factor2 methylation was positively associated with
platelet distribution width (PDW) (Table 3), a measure of
platelet heterogeneity and indirect estimate of megakaryo-
poiesis variation. This association explained 2.6% of PDW
variability (Table 3).
In addition to that, we identified an inverse relation-
ship between both PEAR1 Factor2 and total white blood
cell (WBC) counts and neutrophil percentage and a
positive one with both lymphocyte and monocyte per-
centages (Table 3). PEAR1 methylation could explain
4.6% of neutrophil percentage variability (Table 3).
When adjusting the analysis for platelet variables (plate-
let count, PDW, platelet P-selectin, platelet/monocyte,
and platelet/PMN mixed aggregates), all WBC measure-
ments still remained significantly associated with Factor2
with increased significance and effect of the associations
(Table 4 Model B). When removing the platelet influence
on this association, PEAR1 Factor2 methylation could
explain 5.1, 6.9, and 7.9% of lymphocyte, monocyte, and
granulocyte variability, respectively (Table 4 Model B),
suggesting that the association between PEAR1 methyla-
tion and these cells was independent of thrombopoiesis or
platelet activity.
PEAR1 methylation is associated with markers of
inflammation
Because PEAR1 methylation appeared to be involved at
a different level in platelet and WBC variability, and be-
cause both platelets and leukocytes are mediators of cel-
lular inflammation, we have further investigated whether
PEAR1 methylation would be linked to inflammation
markers, available in the Moli-family cohort. For this
purpose, we studied the association between PEAR1
methylation and markers of platelet and leukocyte acti-
vation and C-reactive protein (CRP) levels.
PEAR1 Factor2 methylation was strongly and signifi-
cantly associated with soluble P-selectin levels following
an inverse relationship (Table 5 Model A). Interestingly,
Table 2 Platelet and WBC variable distribution in the Moli-
family cohort
Variable Moli-family (n = 605)
Platelet measurements
Platelet count, 109/L 249.4 ± 60,6
Mean platelet volume, fL 8.59 ± 0.98
Plateletcrit, % 0.21 ± 0.05
Platelet distribution width, % 16.4 ± 0.6
Soluble P-selectin, μg/L 82.7 ± 38.0
Platelet P-selectin, % 2.76 ± 3.65
Platelet/monocytes aggregates, % 7.24 ± 8.62
Platelet/PMN aggregates, % 4.32 ± 5.02
Inflammation measurements
White blood cell count, 109/L 6.19 ± 1.52
Neutrophils, % 61.0 ± 8.0
Lymphocyte, % 32.0 ± 7.0
Neutrophil/lymphocyte ratio 2.08 ± 0.83
Monocyte, % 7.0 ± 2.0
Red blood cell, 1012/L 4.89 ± 0.5
Platelet/lymphocyte ratio 135.9 ± 47.6
INFLAscore* − 0.23 ± 5.59
C-reactive protein, mg/mL 1.7 ± 1.74
Monocyte L-selectin, % 10.4 ± 7.2
PMN L-selectin, % 25.7 ± 21.3
Monocyte CD11b, % 51.5 ± 24.1
PMN CD11b, % 44.0 ± 25.1
*INFLAscore is calculated as follows: 10 tiles of each biomarker levels (CRP,
WBC, platelets, G/L ratio) were generated. For all four components, being in
the highest deciles (7 to 10) gave a score which increased from 1 to 4, while
being in the lowest deciles (1 to 4) was negatively scored from − 4 to − 1.
Being in the deciles 5 or 6 got zero points. In such a way, the INFLA-score
ranges from − 16 to 16 and comes up as the sum of the four biomarkers. An
increase in the score represented an increase in low-grade
inflammation intensity
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this association could explain 10% of plasma P-selectin
variability (Table 5 Model A). Soluble P-selectin not only
results from platelet activation, but can also be of endo-
thelial cell origin; therefore, we corrected this associ-
ation for platelet-specific covariates (Table 5, Model B).
We observed that, while almost no change occurred
considering the effect (ß values) of PEAR1 methylation
on plasma P-selectin levels, the variability of the same
marker explained by the methylation dropped from 10
to 5% (Table 5, Model B).
PEAR1 Factor2 methylation had a significant positive
relation with expression of CD11b on PMNs and of L-
selectin on both monocytes and PMNs (Table 5). However,
when the model was adjusted for platelet-dependent
covariates (Table 5 Model B), these associations par-
tially decreased in significance, their effect, and the per-
centage of variability, despite residual associations with
PEAR1 methylation, indicative of a relation between
PEAR1 methylation and platelet-dependent but also
platelet-independent inflammation.
We did not find any association between PEAR1 Factor2
and CRP level (Table 5, Model A), but we observed an
inverse association with INFLAscore, a validated composite
marker of low grade inflammation status [42, 43] calcu-
lated from the combination of plasmatic and cellular
biomarkers (CRP levels, platelet and total WBC counts,
and granulocyte/lymphocyte (G/L) ratio, Table 1). This
association that explained the 2.6% of total INFLAscore
variability in the Moli-family cohort, also disappeared when
the model was adjusted for platelet function variables
(PDW, soluble P-selectin, platelet P-selectin, platelet/
monocyte and platelet/PMN) (Table 5, Model B). On the
contrary, the association of PEAR1 Factor2 methylation
with platelet-monocyte mixed aggregates was still signifi-
cant and of similar effect when adjusting the multivariate
model for CRP (Additional file 1: Table S6, Model B).
Replication study in the FLEMENGHO cohort
To replicate the Moli-family findings, we have studied
PEAR1 methylation in 1002 participants belonging to the
FLEMENGHO cohort [37–39]. General characteristics and
blood cell count variables of FLEMENGHO participants
are reported in Additional file 1: Table S7. Because PEAR1
methylation distribution slightly differs among the two
studies, possibly due to underlying population differ-
ences, PCA analysis gave rise to different factors in
FLEMENGHO compared to Moli-family. Therefore, we
have used single CpG analysis to replicate the Moli-
family findings. Interestingly, methylation at CpG4–5,
CpG7–8, CpG11–13, and CpG 19–20 in the
Fig. 1 PEAR1 CGI1 DNA methylation distribution in the Moli-family cohort. Dot-plot representation of PEAR1 CpG unit (depicted on the Y axis)
methylation distribution across the Moli-family participants (N = 605). Mean is shown for each unit as a black bar
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FLEMENGHO cohort was significantly associated with
the percentage of neutrophils and lymphocytes in the
same fashion as in the Moli-family cohort (Add-
itional file 1: Table S8). Measurements of L-selectin ex-
pression on monocytes and PMN were not available for
FLEMENGHO participants; however, circulating L-
selectin was measured [44, 45]. Using the same model,
circulating L-selectin levels in FLEMENGHO were con-
sistently and inversely associated with methylation at
CpG7–8 and CpG19–20 in accordance with Moli-
family data (Additional file 1: Table S8). In addition,
INFLAscore was also negatively associated with
methylation estimates at CpG7.8 and CpG11.13 in
FLEMENGHO, confirming Moli-family results.
Discussion
DNA methylation estimates at the PEAR1 CpG island
(CGI) 1 region are associated with variability of a
series of platelet and WBC parameters ranging from
function/activation (P-selectin, L-selectin, CD11b) to
cell heterogeneity (PDW) and number (WBC, mono-
cytes, and granulocytes).
PEAR1 was first identified as a genetic determinant of
platelet function variability mostly in in vitro assays and
after platelet stimulation [5–12, 14–16, 25–27, 29]. PEAR-
1 in platelets supports activation of the αIIbβ3 integrin [1]
and influences MK precursor proliferation through con-
trol of the PI3K-PTEN pathway [32]. We have already
shown that PEAR1 methylation controls PEAR1 expres-
sion during megakaryopoiesis [30, 46] and is lower in
carriers of rs12041331, a CpG-SNP whose presence alters
the methylation pattern of the PEAR1 intron1 region caus-
ing differential binding of nuclear proteins [30].
We report now, for the first time, that DNA methylation
at the same locus is associated with platelet activation
variability, at baseline in a well-defined population. We
observed an inverse relation between PEAR1 methylation
and platelet-monocyte mixed cell conjugates and with
platelet P-selectin at baseline conditions (Additional file 1:
Tables S4 and S5). Interestingly, we found the CpG sites
mostly involved in this association to be among the ones
described in the MK-specific experiments [30]. In line
with our findings, Wurtz and colleagues [14] reported
rs12041331 (associated with lower methylation) to be
linked to lower platelet aggregation but increased P-
selectin expression. Circulating monocyte-platelet aggre-
gates have been demonstrated to be a sensitive marker of
in vivo platelet activation (together with platelet surface P-
Table 4 Platelets do not influence the association between Factor2 PEAR1 methylation and WBC counts in the Moli-family cohort
Model A Model B
Beta SE p value R-square Beta SE p value R-square
WBC − 0.123 0.058 0.036 0.020 − 0.150 0.054 0.006 0.025
Lymphocytes 0.210 0.055 0.0002 0.009 0.224 0.056 < 0.0001 0.051
Monocytes 0.239 0.055 < 0.0001 0.023 0.268 0.057 < 0.0001 0.069
Granulocytes − 0.275 0.055 < 0.0001 0.046 − 0.286 0.056 < 0.0001 0.079
Model A adjusted by age, gender, BMI, smoking (being an ever smoker and pack-years), drinking (a drinker was defined as drinking daily more than 15 g of
alcohol), being a proband for family recruitment, being a member of MI family as fixed effects, and family as a random effect. Model B is Model A +adjustment by
platelets, PDW, platelet P-selectin, platelet/monocyte, and platelet/PMN. R-squares were calculated using a linear regression model including covariates used as
fixed effect in the mixed models. Standardized values of phenotypes and methylation are reported. Significant p values are reported in italics
Table 5 PEAR1 Factor2 methylation association with markers of cell and plasmatic inflammation partially depends upon platelet
activation n the Moli-family cohort
Model A Model B
Beta SE p value R-square Beta SE p value R-square
Soluble P-selectin − 0.197 0.057 < 0.0001 0.100 − 0.207 0.054 0.0002 0.051
Monocyte CD11b 0.034 0.057 0.549 0.005 0.021 0.057 0.719 0.0004
PMN CD11b 0.122 0.058 0.035 0.043 0.144 0.058 0.014 0.020
Monocyte L-selectin 0.155 0.065 0.019 0.021 0.127 0.066 0.056 0.013
PMN L-selectin 0.151 0.061 0.015 0.059 0.183 0.063 0.004 0.030
CRP − 0.078 0.053 0.145 0.016 − 0.087 0.054 0.112 0.009
INFLAscorea − 0.143 0.058 0.014 0.026 − 0.111 0.059 0.057 0.012
Model A adjusted by age, gender, BMI, smoking (being an ever smoker and pack-years), drinking (a drinker was defined as drinking daily more than 15 g of
alcohol), being a proband for family recruitment, being a member of MI family as fixed effects, and family as a random effect. Model B is Model A +adjustment by
platelets, PDW, platelet P-selectin, platelet/monocyte, and platelet/PMN. aINFLAscore was adjusted only for PDW, soluble P-selectin, platelet P-selectin, platelet-
monocyte aggregates, and platelet-PMN aggregates, but not platelet number, as this variable is accounted in its formula. R-squares were calculated using a linear
regression model including covariates used as fixed effect in the mixed models. Standardized values of phenotypes and methylation are reported. Significant p
values are reported in italics
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selectin) [47]. Platelet-leukocyte conjugates measured in
the Moli-family cohort, as used in the present analysis, are
mainly formed upon platelet but not leukocyte activation
[34]. In addition, PEAR1 methylation-dependent platelet
activation (platelet-monocyte aggregates) is only very
mildly affected by CRP levels (Additional file 1: Table S6),
while yet having a role in influencing inflammation
(Table 5). Indeed, platelet-leukocyte conjugates have
served as a specific marker of platelet activation/function
in several thrombo-inflammatory conditions [48–54].
We did not find any association between PEAR1
(methylation) and platelet counts; however, we did ob-
serve a significant positive relation with PDW, a measure
of platelet size heterogeneity, with possible consequences
on platelet formation and function [55, 56]. In our study,
we could not clarify whether PEAR-1 plays a role in con-
trolling the PDW, because this is not demonstrated by
our analysis; however, we have previously observed that
individuals carrying the A-allele of rs12041331, therefore
showing lower methylation levels at CGI1, also had a
lower number of big MK colony forming units (CFU)
compared to GG homozygotes [30].
Very recently, a possible role of PEAR-1 in controlling
hematopoiesis at large has been suggested by the study
of Eicher and colleagues [25]. In this meta-analysis,
rs12566888, a PEAR1 variant in LD with rs12041331,
was significantly associated with a reduced number of
total WBC, monocytes, and neutrophils. PEAR-1 (JEDI)
was already described to have a role in the fine regula-
tion of the early stages of hematopoietic differentiation,
presumably through the Notch pathway, beside its role
as phagocytic receptor involved in clearing dead sensory
neurons [57]. Our earlier evidence demonstrated transi-
ent PEAR1 expression in myeloid precursors [32].
Further supporting these data, we have recently shown
that the PEAR1 CGI1 region is part of a larger enhancer
that in hematopoietic precursors mediates interactions
with genes that are very active in cell differentiation be-
cause they regulate protein synthesis, cell cycle, and cell
proliferation, possibly via DNA methylation changes
[33]. All these data point to a possible role of PEAR-1 in
driving variability of formation of hematopoietic cells
and are in line with the association of PEAR1 methyla-
tion with white blood cell counts in both Moli-family
and FLEMENGHO cohorts, a link that seems to be
independent from platelets.
In accordance with the identified link between PEAR1
methylation, platelet, and WBC measurements, Factor2
methylation was also associated with other inflammatory
markers. PEAR1 Factor2 methylation can explain about
10% of soluble P-selectin variability, which is remarkable
for a platelet surface molecule, considered to have a modu-
lating role in platelet activation. Yet, the P-selectin associ-
ation may also reflect PEAR1 methylation-mediated effects
in vascular endothelial cells that abundantly express both
PEAR1 and P-selectin [1, 58, 59]. Indeed, when correcting
the association for platelet-specific variables, the variability
of plasma P-selectin levels explained by PEAR1 methyla-
tion was half-sized, suggesting a possible alternative (endo-
thelial) cell origin of plasma P-selectin. In accordance with
the latter, the rs12041331 variant was also described as
a determinant of endothelial cell function [31] and
DNA methylation at PEAR1 is associated with differen-
tial PEAR1 expression in different endothelial cell types
[33]. We also found in the Moli-family cohort a signifi-
cant association with the leukocyte specific activation
markers CD11b and L-selectin and INFLAscore, a com-
posite score integrating both cell and plasmatic inflamma-
tion parameters (Table 5). Adjustment for platelet variables,
however, partially affected these associations, suggesting
that platelet activation determined by PEAR1 methylation
variability can have an impact on inflammation, in agree-
ment with the role of platelets as an inflammatory mediator
[60, 61]. Together with P- and E-selectin, L-selectin medi-
ates the first adhesive step during inflammation [59, 62]
and is rapidly shed from the cell surface upon leukocyte
activation in order to promote cell migration after ex-
travasation [63]. This is in line with the negative associ-
ation of PEAR1 methylation with circulating L-selectin
levels measured in the replication cohort FLEMENGHO.
Together, this evidence suggests that the observed as-
sociation could in part result from platelet-dependent
P-selectin-PSGL-1 interactions on leukocytes, subse-
quently enhancing leukocyte activation and L-selectin
shedding [64, 65].
In conclusion, we report for the first time that PEAR1
methylation is a marker of platelet activation and WBC
count variability, in turn regulating the underlying in-
flammatory status of an individual. By analyzing two in-
dependent cohorts, we were able to provide the first link
between epigenetic gene regulation and platelet biology,
and function variability and hitherto platelet-dependent
inflammatory processes. Future studies should investi-
gate the role of PEAR-1 in hematopoietic specification,
proliferation, and cell function, in relation to its import-
ance for immunity and inflammation regulation and
possible thrombo-inflammatory clinical outcomes.
Materials and methods
Study population
The Moli-family cohort [35, 36] includes 754 white subjects
(≥ 15 years old) from 54 extended pedigrees (23 families
with personal or familial history of early myocardial infarc-
tion (MI)—MI family—and 31 families without) recruited
in the Southern Molise region in Italy. All participants
were relatives of index subjects enrolled in the
population-based Moli-sani study [66, 67]. In all sub-
jects, a complete medical history and information about
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smoking and alcohol-drinking habits were obtained via
a structured questionnaire. Height, body weight, and
blood pressure were measured as described [36, 66]. Blood
samples were obtained between 07:00 and 09:00 from par-
ticipants who had fasted overnight and had refrained from
smoking for at least 6 h. Enrollment and data collection
were performed as previously described [68]. Of the 754
Moli-family participants, 623 had good quality DNA sam-
ples to perform the methylation analysis.
The FLEMENGHO cohort includes 3343 White Euro-
pean participants living in a geographically defined area
of Northern Belgium [37, 39, 69]. The follow-up cycles
between 2005 and 2015 included 1447 participants,
among which 786 and 661 participants had one and two
examinations, respectively. Among 2108 examinations,
1266 DNA or blood samples of 1118 subjects had a good
quality for methylation measurement. For the analysis,
we further excluded subjects with any missing informa-
tion of blood count (n = 37), or CRP (n = 37), or soluble
L-selectin (n = 12). Finally, 1002 FLEMENGHO partici-
pants were included in the current analysis.
In both cohorts, individuals with overt inflammatory
conditions were excluded from the analysis (CRP
levels > 10 mg/dl).
Flow cytometry and biochemical measurements
Moli-family
Mixed platelet-leukocyte conjugates and markers of
platelet or leukocyte activation were measured in the
Moli-family participants as described [34]. Briefly, ven-
ous blood was collected in 3.8% trisodium citrate vacu-
tainer tubes and processed between 10 and 20 min after
collection. Whole blood was then either immediately
fixed using a commercially available fixative (Thrombo-
Fix™, Beckman Coulter Inc.) or stimulated in vitro using
both platelet and leukocyte agonists, namely ADP and
collagen or fMLP, or LTB4, respectively. Details of the
protocol were reported before [34]. Platelet-leukocyte
conjugates, platelet P-selectin, leukocyte CD11b, and L-
selectin expression were measured in whole blood as
described [34]. Platelets, including platelet aggregates,
were defined by morphological characteristics and by
CD42b positivity. PMN and monocyte populations were
defined on the basis of the side scatter (SS) characteris-
tics within the CD45+ population [34].
Biochemical analyses were performed in the central-
ized Moli-sani laboratory. All hematological cytomet-
ric analyses were performed by the same cell counter
(Coulter HMX, Beckman Coulter, IL Milan, Italy),
within 1 h from venipuncture. Soluble P-selectin was mea-
sured in stored plasma via the Human P-selectin Platinum
Enzyme-linked Immunosorbent Assay (ELISA) kit (Affi-
metrix, eBioscience). High-sensitivity (hs) CRP was mea-
sured in serum as described [43, 67].
FLEMENGHO
Hematological cytometric analyses were performed by the
Centrum voor Medische Analysen (Herentals, Belgium).
Randox Laboratories Ltd. (County Antrim, Northern
Ireland, UK) blindly measured CRP and soluble L-selectin
using Biochip Array Technology according to the manu-
facturer’s instructions (Adhesion Molecule and Cerebral II
arrays) and a sandwich assay format [44, 45].
INFLAscore in Moli-family and FLEMENGHO
INFLAscore, which had been previously used within the
Moli-sani cohort [42, 43] to evaluate the possible syner-
gistic effect of both plasma and cellular biomarker of in-
flammation, was calculated in both Moli-family and
FLEMENGHO as described: 10 tiles of each biomarker
levels (CRP, WBC, platelets, granulocyte/lymphocyte (G/L)
ratio) were generated. For all four components, being in
the highest deciles (7 to 10) gave a score which increased
from 1 to 4, while being in the lowest deciles (1 to 4) was
negatively scored from − 4 to − 1. Being in the deciles 5 or
6 got zero points. In such a way, the INFLAscore ranges
from − 16 to 16 and comes up as the sum of the four bio-
markers. An increase in the score represented an increase
in low-grade inflammation intensity.
DNA methylation analysis
PEAR1 (CGI1) methylation was evaluated using the
Sequenom EpiTYPER MassARRAY (Agena) platform as
described [30, 40, 41] on white blood cell DNA from
605 Moli-family and 1002 FLEMENGHO participants.
Bisulfite treatment was conducted on 1 μg of genomic
DNA using the MethylDetector kit (Active Motif) accord-
ing to the manufacturer’s instructions, except for the incu-
bation protocol during the conversion, performed for a
total of 16 h as described [70]. The amplicon to study
PEAR1 methylation was designed using the Sequenom
EpiDesigner software (http://www.epidesigner.com/) [30].
All PCR amplifications were performed in duplicate. For
the CpG-specific analysis, data were discarded when the
duplicate measurements had a SD equal to or greater than
5% [30, 40, 41]. Sequenom peaks with reference intensity
above 2 and overlapping units were excluded from the
analysis [30, 40, 41]. To exclude possible intra-plate differ-
ences, a sample of K562 DNA, with known PEAR1 methy-
lation profile (around 90%), was carried on in each plate.
Statistical analysis
All analyses were performed using SAS/STAT software
(Version 9.4 for Windows©2009. SAS Institute Inc. and
SAS are registered trademarks of SAS Institute Inc.,
Cary, NC, USA).
We used principal component analysis (PCA) on the cor-
relation matrix of the PEAR1 16 CpG sites to identify
PEAR1 methylation patterns in the Moli-family cohort [71].
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We characterized the factors using the PEAR1 methylation
sites with an absolute factor loading greater than 0.25. Cri-
teria for number of factor selection were eigenvalue > 1.0 as
revealed by the scree test. Each subject received a factor
score, calculated by summing the observed methylation site
values, each weighted by factor loadings. Linear mixed re-
gression models were used to evaluate associations between
PEAR1 methylation factors or single CpG sites and pheno-
types. Age, gender, BMI, smoking (being an ever smoker
and pack-years), alcohol drinking (a drinker was defined as
drinking daily more than 15 g of alcohol), being a proband
for family recruitment, and being a member of MI family
were treated as fixed effects, and family stratification as a
random effect. R-squares were calculated using a linear
regression model including covariates used as fixed effect in
the mixed models. Platelet parameters or CRP were used
where appropriate as indicated below to verify their poten-
tial role as confounders on the effect of PEAR1 methylation
on white blood cell or platelet parameters.
To replicate the Moli-family findings in FLEMEN-
GHO, we used a multivariate regression model with age,
gender, BMI, smoking (being an ever smoker and pack-
years), and drinking (a drinker was defined as drinking
daily more than 15 g of alcohol) as covariates.
A false discovery rate (FDR) method (Benjamini-
Hochberg) were used to adjust p values for multiple
testing with a p value (pFDR) < 0.05 considered as
statistically significant.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-019-0744-8.
Additional file 1. Tables S1-S8.
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